MANKIND - Mankind Pharma
📢 Recent Corporate Announcements
Mankind Pharma Limited has successfully appealed against a GST penalty order originally issued in December 2024. The Additional Commissioner of CGST (Appeals), Meerut, has issued an order dropping the penalty of INR 1,02,05,688 that was previously imposed for the period FY 2017-18 to 2020-21. This decision clears the company of the specific financial liability mentioned in the original order. While the amount is relatively small for a company of Mankind's scale, it represents a successful resolution of a regulatory dispute.
- CGST (Appeals) Meerut drops a penalty of INR 1,02,05,688 against Mankind Pharma.
- The dispute related to the financial years 2017-18 through 2020-21.
- The order follows an appeal filed by the company against a previous order dated December 27, 2024.
- The company stated there is no further quantifiable financial or operational impact from this specific matter.
Mankind Pharma Limited has scheduled its participation in the 'Chasing Growth 2026' investor conference on February 24, 2026, in Mumbai. The company management will engage in one-on-one and group meetings with institutional investors to discuss business trends. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions. This is a standard regulatory disclosure aimed at maintaining transparency with the investment community.
- Participation in 'Chasing Growth 2026' conference scheduled for February 24, 2026.
- Interaction format includes both one-on-one and group meetings with institutional investors.
- The event will take place in Mumbai as part of routine investor relations activity.
- Company confirms that no unpublished price sensitive information (UPSI) will be disclosed.
Mankind Pharma Limited has received a favorable ruling from the Joint Commissioner of State Tax (Appeals), Nagpur. The order drops a previously imposed penalty of INR 46,32,582 related to the financial year 2020-21. This decision follows an appeal filed by the company against an earlier order dated February 28, 2025, issued under Section 73 of the CGST Act, 2017. The company has confirmed that this development has no further material impact on its financial or operational activities.
- Joint Commissioner of State Tax (Appeals) dropped a penalty of INR 46,32,582.
- The dispute pertained to the financial year 2020-21 under Section 73 of the CGST Act.
- The order reverses a previous demand issued by the Deputy Commissioner of State Tax, Nagpur.
- The ruling provides legal relief from a contested tax demand in Maharashtra.
The GST Department, Mumbai, conducted a search and inspection operation at Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary of Mankind Pharma. The operation took place over six days, from February 3 to February 8, 2026, under Section 67 of the Maharashtra GST Act. The inspection focused on tax payments, input tax credit claims, reconciliation, and refunds. Mankind Pharma has officially stated that the search has resulted in no material impact on the subsidiary's financials or operations.
- Search conducted by Assistant Commissioner of State Tax (Investigation – B), Mumbai
- Operation lasted 6 days from February 3 to February 8, 2026
- Focus areas included GST tax payments, input tax credit (ITC) reconciliation, and refunds
- Management confirms no material impact on BSV's financial or operational activities
- BSV is a wholly owned unlisted subsidiary of Mankind Pharma Limited
Mankind Pharma reported a steady Q3 FY26 with revenue growing 11.5% YoY to INR 3,567 crores, driven by an 11.1% increase in domestic sales and 14% growth in exports. The company's adjusted EBITDA margin stood at 25.9%, while the chronic segment's contribution rose to 36.7% of total sales. Integration of the BSV acquisition showed positive results with double-digit growth, and the company successfully reduced its net debt to INR 4,294 crores. Management highlighted a recovery in volume growth and significant outperformance in cardio and anti-diabetic therapies compared to the market.
- Q3 FY26 revenue increased 11.5% YoY to ₹3,567 crores with an adjusted EBITDA margin of 25.9%.
- Chronic therapy contribution rose to 36.7%, with cardio and anti-diabetes growing at 16.7% and 14.4% respectively.
- Export revenue for 9M FY26 surged 51% YoY to ₹1,503 crores, supported by EU GMP certification for the Udaipur facility.
- Net debt reduced to ₹4,294 crores, bringing the net debt to adjusted EBITDA ratio down to 1.3x.
- Domestic PCPM improved to ₹7.2 lakhs from ₹6.5 lakhs on a trailing 12-month basis.
Mankind Pharma Limited has scheduled participation in two major institutional investor conferences in Mumbai. The company will attend the Systematix India Annual Flagship Conference on February 9, 2026, followed by Axis Capital's Flagship India Conference on February 10, 2026. These interactions will consist of one-on-one and group meetings with institutional investors. The company has explicitly stated that no unpublished price sensitive information will be shared during these sessions.
- Participation in Systematix India's 'MANTHAN' conference on February 9, 2026.
- Participation in Axis Capital's 'Advantage India' conference on February 10, 2026.
- Meetings will be conducted in both One-on-One and Group formats in Mumbai.
- Company confirms no unpublished price sensitive information (UPSI) will be disclosed.
Mankind Pharma Limited has released the audio recording of its investor conference call for the third quarter and nine months ended December 31, 2025 (FY26). The call was held on February 3, 2026, following the company's quarterly earnings announcement. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations, 2015. The recording allows investors to hear management's detailed commentary on financial performance and future growth strategies.
- Audio recording for Q3 and 9M FY26 earnings call is now publicly available.
- The conference call with senior management was conducted on February 3, 2026.
- The filing is in compliance with SEBI Listing Obligations and Disclosure Requirements.
- Recording link is hosted on the official Mankind Pharma website for transparency.
Mankind Pharma reported a steady performance for Q3 FY26 with standalone revenue from operations at ₹2,632.68 crore, showing a marginal sequential dip from ₹2,636.95 crore in Q2. Standalone Profit After Tax (PAT) stood at ₹449.47 crore, slightly lower than the ₹462.27 crore reported in the previous quarter, partly due to an exceptional item of ₹83.42 crore. The financial results have been restated to account for the acquisition of Bharat Serums and Vaccines Limited (BSV) and other business combinations. Overall, the company maintains a strong balance sheet with a total comprehensive income of ₹452.53 crore for the quarter.
- Standalone Revenue from operations stood at ₹2,632.68 crore for the quarter ended December 31, 2025.
- Standalone Profit After Tax (PAT) reached ₹449.47 crore, impacted by an exceptional charge of ₹83.42 crore.
- Basic Earnings Per Share (EPS) for the quarter was reported at ₹10.89.
- Financials were restated to reflect the impact of the Bharat Serums and Vaccines Limited (BSV) acquisition.
- Total expenses for the quarter were managed at ₹2,100.49 crore compared to ₹2,189.09 crore in the preceding quarter.
Mankind Pharma reported a steady 11.5% YoY revenue growth in Q3 FY26, reaching ₹3,567 crore, primarily driven by domestic pharma and the consolidation of BSV. The company's chronic segment showed strong momentum, with its share increasing by 200bps to 39.3%, led by high growth in Cardiac (16.7%) and Anti-Diabetes (14.4%) therapies. While reported EBITDA margins were 22.9%, adjusted margins stood at 25.9% after accounting for one-time labor code impacts. The Consumer Healthcare segment regained momentum with 5.2% growth, and the export business grew by 14.1% YoY.
- Revenue from operations grew 11.5% YoY to ₹3,567 crore, with domestic business contributing ₹3,046 crore.
- Chronic segment share increased to 39.3% from 37.3% YoY, significantly outperforming the Indian Pharma Market (IPM) in key therapies.
- Adjusted EBITDA margin stood at 25.9%, while PAT grew 9.5% YoY to ₹414 crore.
- Export business witnessed 14.1% YoY growth, reaching ₹521 crore, aided by BSV international business.
- Net debt reduced to ₹4,294 crore as of Dec 31, 2025, from ₹6,739 crore in Dec 2024, showing strong cash flow utilization.
Mankind Pharma reported a steady 11.5% YoY revenue growth in Q3 FY26, reaching ₹3,567 crore, primarily driven by domestic pharma and the consolidation of BSV. The company's chronic segment share improved by 200bps to 39.3%, with strong performance in cardiac (16.7%) and anti-diabetes (14.4%) therapies. While reported EBITDA margins saw compression to 22.9% due to one-time costs, the adjusted EBITDA margin remained healthy at 25.9%. Consumer healthcare showed signs of recovery with 5.2% growth compared to a decline in the previous quarter.
- Revenue from operations grew 11.5% YoY to ₹3,567 Cr, with domestic revenue up 11.1% to ₹3,046 Cr.
- Chronic therapy share increased to 39.3% of total revenue, led by 16.7% growth in Cardiac and 14.4% in Anti-Diabetics.
- Adjusted EBITDA margin stood at 25.9% after adjusting for one-time labor code impacts and non-recurring costs.
- Consumer Healthcare (OTC) returned to growth at 5.2% YoY, a significant recovery from the -2.6% growth in Q2 FY26.
- Export revenue increased 14.1% YoY to ₹521 Cr, supported by the BSV international business.
Mankind Pharma reported a standalone revenue of ₹2,632.68 crore for the quarter ended December 31, 2025, remaining largely flat compared to ₹2,636.95 crore in the previous quarter. Net profit for the period stood at ₹449.47 crore, a slight sequential decline from ₹462.27 crore, partly due to an exceptional item of ₹83.42 crore. The financials have been restated to incorporate the acquisition of Bharat Serums and Vaccines Limited (BSV). The company also noted ongoing income tax litigation which is currently under appeal.
- Standalone Revenue from operations recorded at ₹2,632.68 crore for Q3 FY26
- Profit After Tax (PAT) reached ₹449.47 crore, down 2.7% sequentially
- An exceptional item of ₹83.42 crore impacted the quarterly bottom line
- Financial results restated to reflect the business combination with Bharat Serums and Vaccines Limited (BSV)
- Basic EPS for the quarter stood at ₹10.89 compared to ₹11.20 in the preceding quarter
Mankind Pharma has announced the withdrawal of its (ICRA) A1+ credit rating for Commercial Paper worth ₹1,500 crore at its own request. Despite this withdrawal, the company's core credit profile remains strong with an outstanding (ICRA) AA+/Stable rating for its ₹5,000 crore Non-Convertible Debentures. Additionally, fund-based limits totaling ₹1,250 crore retain their high-grade (ICRA) AA+ (Stable) and (ICRA) A1+ ratings. This update confirms that the company's creditworthiness and ability to service debt remain robust.
- ICRA withdrew the (ICRA) A1+ rating for ₹1,500 crore Commercial Paper at the company's request.
- Outstanding rating for ₹5,000 crore Non-Convertible Debentures remains stable at (ICRA) AA+.
- Long-term and short-term fund-based limits of ₹1,250 crore maintain (ICRA) AA+ (Stable) and (ICRA) A1+ ratings.
- The withdrawal of the CP rating is a procedural action and does not indicate a downgrade in credit quality.
Mankind Pharma Limited has scheduled its investor conference call to discuss the financial results for the third quarter and nine months ended December 31, 2025 (FY26). The call is slated for Tuesday, February 3, 2026, at 06:00 PM IST. Senior management, including the Vice Chairman, CEO, and Global CFO, will be present to discuss the company's business performance and outlook. This is a standard regulatory disclosure following SEBI requirements.
- Earnings call scheduled for February 3, 2026, at 6:00 PM IST to discuss Q3 and 9M FY26 results.
- Senior management participation includes Vice Chairman Rajeev Juneja and Global CFO Ashutosh Dhawan.
- Universal dial-in numbers provided are +91 22 6280 1102 and +91 22 7115 8003.
- The company has provided international toll-free numbers for USA, UK, Singapore, and Hong Kong.
Mankind Pharma Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar and Share Transfer Agent, KFin Technologies, confirmed that no requests for dematerialization or rematerialization of shares were received during the quarter from October 1, 2025, to December 31, 2025. This is a standard administrative filing required by SEBI to ensure the integrity of electronic shareholding records. The filing indicates a stable shareholding structure with no physical-to-electronic conversion activity during the period.
- Compliance certificate submitted for the quarter ended December 31, 2025
- Zero requests received for dematerialization or rematerialization of shares during the quarter
- Confirmation provided by Registrar and Share Transfer Agent, KFin Technologies Limited
- Filing adheres to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Mankind Pharma Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This mandatory regulatory step is taken in anticipation of the declaration of the company's unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The trading window will remain closed until 48 hours after the financial results are made public. The specific date for the board meeting to approve these results will be communicated at a later date.
- Trading window closure effective from January 1, 2026.
- Closure pertains to the financial results for the quarter and nine months ending December 31, 2025.
- Restriction applies to designated persons, their immediate relatives, and related financial associates.
- The window will reopen 48 hours after the official announcement of financial results.
Financial Performance
Revenue Growth by Segment
Domestic Business grew 14.5% YoY to INR 3,184 Cr (86.1% of revenue), while Exports surged 82.6% YoY to INR 513 Cr (13.9% of revenue) due to BSV consolidation. The Consumer Healthcare segment saw a 2.6% YoY decline to INR 226 Cr, impacted by supply chain disruptions and monsoon patterns.
Geographic Revenue Split
Domestic market accounts for approximately 86.1% of revenue (INR 3,184 Cr in Q2 FY26), while Exports contribute 13.9% (INR 513 Cr). Historically, the domestic market has represented up to 92% of total operating income.
Profitability Margins
Gross Margin stood at 71.3% (down 20 bps YoY), EBITDA Margin at 25.0% (down 280 bps YoY), and PAT Margin at 14.1% (down 750 bps YoY) for Q2 FY26.
EBITDA Margin
25.0% in Q2 FY26, representing a 280 bps YoY decline from 27.8% in Q2 FY25. This contraction was driven by the consolidation of BSV and one-time discounts provided to stockists during the GST 2.0 transition.
Capital Expenditure
INR 163 Cr spent in Q2 FY26 (4.4% of revenue). The company maintains a guidance of 5% of revenue for FY26 capex, with organic capex expected at INR 600-800 Cr per annum over the medium term.
Credit Rating & Borrowing
CRISIL Ratings maintains a 'Stable' outlook. Net debt to adjusted EBITDA improved to 1.4x in Q2 FY26 from 1.8x in March 2025, following the repayment of INR 3,000 Cr in commercial paper using QIP proceeds.
Operational Drivers
Capacity Expansion
Organic capex of INR 600-800 Cr per annum planned over the medium term to support growth.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but 75% in-house manufacturing supports a healthy gross margin of 71.3%.
Manufacturing Efficiency
PCPM (Per Candidate Per Month) for the domestic business improved to INR 7 Lakhs (TTM basis) from INR 6.8 Lakhs. BSV specialty business PCPM improved to INR 12.6 Lakhs from INR 11.1 Lakhs.
Strategic Growth
Expected Growth Rate
12-15%
Growth Strategy
Mankind aims to achieve growth through the integration of Bharat Serums and Vaccines (BSV), acquired for INR 13,768 Cr, which provides access to high-entry-barrier specialty segments like women's health and fertility. The company is shifting its portfolio towards the Chronic segment, which now accounts for 36% of revenue and grew at 13.5% (outperforming IPM's 13.3%). Additionally, Mankind leverages its massive distribution network of 18,000+ field force and 500,000 doctors to drive a 1.7x volume outperformance compared to the Indian Pharmaceutical Market (IPM).
Products & Services
Pharmaceutical formulations for acute and chronic therapies, Manforce condoms, Gas-O-Fast antacids, Prega News pregnancy kits, fertility hormones, and critical care medicines.
Brand Portfolio
Manforce, Gas-O-Fast, Prega News, HealthOK, and BSV specialty brands.
New Products/Services
BSV specialty portfolio and new chronic therapy launches; new products achieved 1.7x volume outperformance vs the industry.
Market Expansion
Focus on Tier 2 and below cities (45% of revenue) and expanding the specialty/super-specialty presence through BSV integration.
Market Share & Ranking
4th largest pharmaceutical company in India by value; 1st in prescription share at 15.3%.
Strategic Alliances
Completed the 100% acquisition of Bharat Serums and Vaccines (BSV) for INR 13,768 Cr in October 2024.
External Factors
Industry Trends
The Indian Pharmaceutical Market (IPM) is growing at 8%, with a significant shift toward chronic therapies. Mankind is positioning itself by increasing its chronic revenue share to 36% and acquiring BSV to lead in the specialty super-specialty segments. The industry is also seeing a digital shift, with Mankind's Modern Trade and E-commerce share rising from 8% to 12% in H1 FY26, supported by 45%+ growth in these channels.
Competitive Landscape
Competes with top Indian pharma players; maintains a notch lower price increase (3.9%) than IPM (4.2%) to gain volume share.
Competitive Moat
Mankind possesses a durable moat through its extensive distribution network, reaching 500,000 doctors and maintaining the highest prescription share in India at 15.3%. Its 75% in-house manufacturing provides cost leadership and supply chain control. The acquisition of BSV adds a specialty moat with complex R&D platforms and high-entry-barrier products in critical care and fertility, where competition is limited.
Macro Economic Sensitivity
Sensitive to monsoon cycles (impacting OTC/Acute sales) and domestic GDP growth, as 86-92% of revenue is India-centric.
Consumer Behavior
Rapid shift to digital channels, with Modern Trade and E-commerce growing at 45%+ YoY.
Geopolitical Risks
Low international exposure as exports only contributed ~8-14% to total operating income.
Regulatory & Governance
Industry Regulations
Subject to DPCO/NLEM price caps on 16% of the portfolio; non-scheduled products (85%) allowed 10% annual price hikes.
Environmental Compliance
ESG compliance mentioned as key for capital raising and stakeholder confidence.
Legal Contingencies
The company faces a potential contingent tax liability of approximately INR 1,000 Cr following Income Tax assessment orders and disallowances of over INR 1,800 Cr. While management considers these demands untenable, an adverse outcome would materially impact the financial risk profile.
Risk Analysis
Key Uncertainties
Integration risks of the INR 13,768 Cr BSV acquisition, outcome of the INR 1,000 Cr tax dispute, and high dependence on the Indian market (92%).
Geographic Concentration Risk
92% of revenue from India; 45% from Tier 2 and below cities.
Third Party Dependencies
25% of manufacturing is outsourced to third-party vendors.
Technology Obsolescence Risk
Implementing AI-powered virtual learning (Mankind University) to modernize the workforce and mitigate digital transformation risks.
Credit & Counterparty Risk
Efficient working capital management with 46 days cycle and minimal credit line utilization.